Nuvation Bio Agrees To Acquire AnHeart Therapeutics in All-Stock Transaction; Nuvation Bio Will Issue Approximately 43.6M Shares To AnHeart At The Closing Of The Acquisition Which Is Expected In Q2 2024

Immediately following the closing of the Acquisition, the former shareholders of AnHeart will own approximately 33% and the current stockholders of Nuvation Bio will own approximately 67% of Nuvation Bio on a fully diluted basis. The Acquisition, which has been approved by the board of directors of each company and is subject to approval by AnHeart's shareholders and other customary closing conditions, will position Nuvation Bio as a late-stage global oncology company with multiple programs in clinical development.